SCHEDULE: Column Group Reduces Tenaya Therapeutics Stake

The Column Group entities, including managing partners Tim Kutzkey and Peter Svennilson, reported significant sales of Tenaya Therapeutics common stock in early February 2026.

Summary

• The Column Group III, LP (TCG III LP) sold an aggregate of 161,422 shares of Tenaya Therapeutics' Common Stock on February 10, 2026, at a weighted-average price of $0.8161 per share, totaling approximately $0.13 million.
• TCG III-A LP sold an aggregate of 182,295 shares of Tenaya Therapeutics' Common Stock on February 10, 2026, at a weighted-average price of $0.8161 per share, totaling approximately $0.15 million.
• On February 11, 2026, TCG III LP sold an additional 1,905,115 shares at a weighted-average price of $0.6808 per share, for approximately $1.3 million.
• TCG III-A LP also sold an additional 2,151,458 shares on February 11, 2026, at a weighted-average price of $0.6808 per share, for approximately $1.46 million.
• Following these transactions, Tim Kutzkey and Peter Svennilson, as managing partners/members of the controlling entities, beneficially own 54,313,559 shares, representing 25.4% of Tenaya Therapeutics' Common Stock.
• The Column Group Opportunity III, LP (TCG Opportunity III LP) beneficially owns 49,313,559 shares, representing 23.1% of the class, excluding warrants to purchase 53,571,426 shares not exercisable within 60 days due to beneficial ownership limitations.
• The total outstanding shares of Common Stock for Tenaya Therapeutics, Inc. were 213,744,535 as of December 15, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development given the substantial share sales by a major institutional investor, potentially signaling reduced confidence or a strategic exit, which could exert downward pressure on the stock price.

Negatives

• Significant share sales by major institutional investors (The Column Group entities) totaling 4,400,290 shares over two days.
• The sales occurred at declining prices, from a weighted-average of $0.8161 per share on February 10, 2026, to $0.6808 per share on February 11, 2026.

Risks

• The substantial reduction in stake by a major institutional investor could be perceived negatively by the market, potentially signaling a lack of confidence in Tenaya Therapeutics' future prospects or a shift in the investor's portfolio strategy.
• The exclusion of warrants to purchase 53,571,426 shares held by TCG Opportunity III LP, due to beneficial ownership limitations, indicates a potential for future dilution if these warrants become exercisable and are converted.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that significant divestment by a major venture capital firm like The Column Group, especially in the biotechnology sector, can sometimes signal a shift in their portfolio strategy or a re-evaluation of the investee company's near-term prospects. Such sales, particularly at declining prices, may prompt other investors to scrutinize the company's fundamentals and future outlook more closely.

Stakeholder Impact

• Shareholders may perceive the significant sales by a major institutional investor as a negative signal, potentially leading to downward pressure on the stock price due to concerns about the company's future prospects or valuation.
• The reduction in a major investor's stake could impact the company's ability to raise future capital or attract new institutional investors, as it might be seen as a lack of long-term commitment.

Key Dates

Recommendation

The substantial divestment by a major institutional investor like The Column Group, particularly at declining prices, suggests a loss of confidence or a strategic exit. This action could signal underlying concerns about Tenaya Therapeutics' future prospects or valuation, making it prudent for investors to consider selling their holdings.

Keywords

Tenaya Therapeutics, TNYA, The Column Group, Schedule 13D, beneficial ownership, stock sales, institutional investor, venture capital, biotechnology